Drugmaker Johnson & Johnson says it will be able to provide 20 million US doses of its single-shot Covid-19 vaccine by the end of March, assuming it gets the greenlight from federal regulators.
J&J disclosed the figure in written testimony ahead of a Congressional hearing on Tuesday looking at the country's vaccine supply. White House officials cautioned last week that initial supplies of J&J's vaccine would be limited.
The company reiterated that it will have capacity to provide 100 million vaccine doses to the US by the end of June. That supply will help government officials reach the goal of having enough injections to vaccinate most adult Americans later this year. On a global scale the company aims to produce 1 billion doses this year.
US health regulators are still reviewing the safety and effectiveness of the shot and a decision to allow its emergency use is expected later this week. J&J's vaccine would be the first in the US that requires only a single shot.
Currently available vaccines from Pfizer and Moderna require two doses spaced several weeks apart. Executives from both companies and two other vaccine makers will also testify at Tuesday's hearing.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.